5 Key Takeaways
-
1
Bausch + Lomb and Bausch Health announced that CEO Brent Saunders and the board mutually agreed to his departure, without providing an explanation.
-
2
Thomas J. Appio, Bausch + Lomb board chairman and Bausch Health CEO, became interim CEO effective immediately while continuing to lead Bausch Health.
-
3
Saunders returned to lead Bausch + Lomb in 2023, having previously served as its CEO from 2010 to 2013.
-
4
The companies expect to raise full-year 2026 adjusted EBITDA guidance, excluding acquired in-process research and development expenses, based on preliminary third-quarter results.
-
5
Bausch + Lomb has not announced a timeline for naming a permanent successor to Saunders.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
